Hostname: page-component-76fb5796d-5g6vh Total loading time: 0 Render date: 2024-04-26T22:07:41.745Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical Experience with Sulthiame (Ospolot)

Published online by Cambridge University Press:  29 January 2018

M. C. Liu
M. C. Liu*
Affiliation:
Monyhull Hospital, King's Heath, Birmingham, 14
Get access Rights & Permissions [Opens in a new window]

Extract

The anticonvulsants now in general use have made epilepsy among the mentally subnormal no longer the problem it was. However, the treatment of long standing epilepsy associated with behaviour problems or personality disorders in the so-called temporal lobe syndrome still remains a challenge. Surgical intervention seldom has a place in cases with severe and diffuse brain damage complicated by subnormal intellectual functioning, frequent seizures and personality changes.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 112 , Issue 487 , June 1966 , pp. 621 - 628
Copyright
Copyright © Royal College of Psychiatrists, 1966 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Davies, T. S., and Leyshon, M. W. (1963). “Ospolot in epilepsy.” Lancet, ii, 939–40.Google Scholar
Flügel, F., Bente, D., and Itil, T. (1960). “The position of the butanesultam derivative Ospolot in the treatment of cerebral convulsive diseases.” Dtsch. med. Wschr., 85, 2199.Google Scholar
Garland, H. G., and Sumner, D. W. (1964). “Sulthiame in treatment of epilepsy.” Brit. med. J., i, 474–6.Google Scholar
Gordon, N. (1964). “The use of Ospolot in the treatment of epilepsy.” Epilepsia, 5, 68–73.CrossRefGoogle Scholar
Griffiths, A. W., and Sylvester, P. E. (1964). “Ospolot —a clinical trial of a new anticonvulsant.” Brit. J. Psychiat., 110, 261–6.CrossRefGoogle Scholar
Haran, T. (1962). “Ospolot: a preliminary communication.” Irish J. med. Sci., 427–31.Google Scholar
Kluge, D. (1962). “Clinical experience with Ospolot.” Symposia on Modern Therapeutic Problems, 4, 19.Google Scholar
Krüger, H. J. (1962). “Clinical experience with Ospolot.” Ibid., 4, 10–18.Google Scholar
LaVeck, G. D., de la Cruz, F., and Thomas, D. B. (1962). “Clinical evaluation of a new anticonvulsant, Sulthiame.” Neurology, (Minneap.), 12, 923–8.CrossRefGoogle Scholar
Laubenthal, F., and Raffauf, H. J. (1962). “Secondary and side effects during administration of Ospolot.” Symposia on Modern Therapeutic Problems, 4, 132–41.Google Scholar
Raffauf, H. J. (1960). “Treatment of cerebral convulsive diseases with Ospolot.” Dtsch. med. Wschr., 85, 2203.CrossRefGoogle Scholar
Selbach, H. (1962). “General discussion on Ospolot.” Symposia on Modern Therapeutic Problems, 4, 145.Google Scholar
Wirth, W., Hoffmeister, F., Friebel, H., and Sommer, S. (1960). “Pharmacological studies of N- (4′-sulphamylphenyl)-butanesultam (1–4).” Dtsch. med. Wschr., 85, 2195.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.